It takes two: After making its commercial debut early this year, Dexcom’s latest continuous glucose monitor is wrapping up 2023 by connecting with its first automated insulin pump partner, courtesy of ...
DexCom is a leading healthcare stock that has seen significant growth, with shares returning close to 1,400% in the past decade. DXCM stock has faced resistance and is currently 37% below its all-time ...
Hosted on MSN
DexCom: Revenue Up, EPS Misses Mark
DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue, which ...
Shares of medical device company DexCom (NASDAQ:DXCM) jumped 3.7% in the afternoon session after it rebounded from a steep sell-off that was triggered by its long-term revenue growth outlook. The ...
Insulet Corp. reported much better than expected fourth quarter results, following on Dexcom Inc.’s report of earlier than expected coverage decision from CMS for its just-approved G7 continuous ...
DexCom Q4 revenue beat at $1.114B, up 8% Y/Y, but EPS missed at $0.45 vs. $0.50 consensus. FY25 guidance reaffirmed with $4.6B revenue target and 21% operating margin. Get stock picks, daily rankings, ...
Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Dexcom, Inc. Today, prominent investor rights law firm Bernstein Litowitz ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback